Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.

{"article_title":"Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP\/IASLC\/AMP Guideline Recommendations: A Single-center Analysis.","author":"DiStasio M, Chen Y, Rangachari D, Costa DB, Heher YK, VanderLaan PA","journal_title":"Clinical lung cancer","issn":"1938-0690","isbn":"","publication_date":"2017 Sep","volume":"18","issue":"5","first_page":"e349","page_count":"","accession_number":"28377205","doi":"10.1016\/j.cllc.2017.03.001","publisher":"Elsevier","doctype":"Journal Article","subjects":"Carcinoma, Non-Small-Cell Lung genetics; DNA, Neoplasm analysis; Genetic Testing statistics & numerical data; Lung Neoplasms genetics; Specimen Handling statistics & numerical data; Anaplastic Lymphoma Kinase; DNA Mutational Analysis; ErbB Receptors genetics; Feasibility Studies; Female; Genetic Testing standards; Humans; In Situ Hybridization, Fluorescence; Male; Molecular Targeted Therapy; Practice Guidelines as Topic; Protein-Tyrosine Kinases genetics; Proto-Oncogene Proteins genetics; Proto-Oncogene Proteins p21(ras) genetics; Receptor Protein-Tyrosine Kinases genetics; Retrospective Studies; Specimen Handling standards; Time Factors; Workflow","interest_area":["Oncology"," Pulmonology"," Radiology"],"abstract":"Introduction: Molecular testing to identify targetable driver mutations is the standard of care for patients with advanced-stage non-small cell lung cancer. Recent guideline recommendations by the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) established a benchmark turnaround time (TAT) target of 10 working days for results to be available to the treating oncologist and ? 3 days for specimens to arrive at a commercial testing laboratory if testing is not performed in-house. Methods and Materials: To provide insights regarding the pre-testing, post-testing, and testing intervals that constitute the overall TAT target, we performed a detailed workflow analysis. A total of 157 lung cancer specimens were sent out for molecular testing at a commercial vendor from a single academic medical center during the calendar year 2015. Results: Overall, 128 specimens (81.5%) met the recommended 10-working day TAT, with a median total TAT of 9 weekdays (mean \ufffd standard deviation, 9.17 \ufffd 4.15 days). The pre-testing interval was ? 3 days for 146 specimens (93.0%), and the post-testing reporting interval was < 1 day for 116 cases (73.9%). The TAT variance was not related to intrinsic specimen characteristics. Conclusion: Overall, the findings indicated that the CAP\/IASLC\/AMP TAT guideline recommendations are feasible for most lung cancer specimens when a streamlined system is in place. Copyright \ufffd 2017 Elsevier Inc. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=28377205&authtype=shib&custid=ns346513","isPdfLink":true,"isSAML":false,"additionalInfo":{"Authored_By":"DiStasio M, Chen Y, Rangachari D, Costa DB, Heher YK, VanderLaan PA","Journal_Info":"Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE","Publication_Type":"Journal Article","Published_Date":"2017-09-01","Source":"Clinical lung cancer [Clin Lung Cancer] 2017 Sep; Vol. 18 (5), pp. e349-e356. Date of Electronic Publication: 2017 Mar 14.","Languages":"English","Electronic_ISSN":"1938-0690","MeSH_Terms":"Carcinoma, Non-Small-Cell Lung\/*genetics , DNA, Neoplasm\/*analysis , Genetic Testing\/*statistics & numerical data , Lung Neoplasms\/*genetics , Specimen Handling\/*statistics & numerical data, Anaplastic Lymphoma Kinase ; DNA Mutational Analysis ; ErbB Receptors\/genetics ; Feasibility Studies ; Female ; Genetic Testing\/standards ; Humans ; In Situ Hybridization, Fluorescence ; Male ; Molecular Targeted Therapy ; Practice Guidelines as Topic ; Protein-Tyrosine Kinases\/genetics ; Proto-Oncogene Proteins\/genetics ; Proto-Oncogene Proteins p21(ras)\/genetics ; Receptor Protein-Tyrosine Kinases\/genetics ; Retrospective Studies ; Specimen Handling\/standards ; Time Factors ; Workflow","Subjects":"Anaplastic Lymphoma Kinase, DNA Mutational Analysis, ErbB Receptors genetics, Feasibility Studies, Female, Genetic Testing standards, Humans, In Situ Hybridization, Fluorescence, Male, Molecular Targeted Therapy, Practice Guidelines as Topic, Protein-Tyrosine Kinases genetics, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins p21(ras) genetics, Receptor Protein-Tyrosine Kinases genetics, Retrospective Studies, Specimen Handling standards, Time Factors, Workflow, Carcinoma, Non-Small-Cell Lung genetics, DNA, Neoplasm analysis, Genetic Testing statistics & numerical data, Lung Neoplasms genetics, Specimen Handling statistics & numerical data","Title_Abbreviations":"Clinical lung cancer","Volume":"18"},"header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"28377205","RelevancyScore":"808","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"808.320617675781"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=28377205&authtype=shib&custid=ns346513&group=main&profile=eds","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=28377205&authtype=shib&custid=ns346513&group=main&profile=eds"}